merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>Lower price and FDA approval</answer>
<question_number>2</question_number>
<answer>By offering a cheaper, FDA-approved alternative that can be delivered directly to patients</answer>
<question_number>3</question_number>
<answer>Lack of oversight and potential safety issues</answer>
<question_number>4</question_number>
<answer>Attracts price-sensitive customers and positions Zepbound as a safer, more reliable option</answer>
<question_number>5</question_number>
<answer>Once off the shortage list, there should be no need for compounded versions</answer>
<question_number>6</question_number>
<answer>Reflects a trend towards more transparent and direct pricing models</answer>
<question_number>7</question_number>
<answer>May lead to more Medicare patients opting for Zepbound vials despite the lack of coverage for weight-loss drugs</answer>
<question_number>8</question_number>
<answer>Could lead patients to perceive Zepbound vials as a safer and more regulated option</answer>
<question_number>9</question_number>
<answer>Being listed as "in shortage" by the FDA</answer>
<question_number>10</question_number>
<answer>Lowering prices to compete directly with compounding pharmacies</answer>